BioSpace News Archive

Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, today announced that the U.S. Food and Drug Administration (FDA) has allowed an Investigational New Drug Application (IND) to proceed for its first genetically modified TIL therapy, IOV-4001.

Surgalign Holdings, Inc., a global medical technology company focused on elevating the standard of care by driving the evolution of digital surgery, reported operating results for the fourth quarter and full year 2021.

Ra Medical Systems, Inc. (NYSE American: RMED) announces that it will report 2021 fourth quarter and full year financial results after market close on Wednesday, March 23. Ra Medical management will hold an investment community conference call that day at 1:30 p.m. Pacific time (4:30 p.m. Eastern time) to discuss financial results and provide a company update.

Adicet Bio, Inc., a clinical stage biotechnology company discovering and developing first-in-class allogeneic gamma delta chimeric antigen receptor T cell therapies for cancer, reported financial results and operational highlights for the fourth quarter and year ended December 31, 2021.

Atara Biotherapeutics, Inc., a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, will host an EBV and multiple sclerosis Day on Tuesday, March 22, 2022 from 4:00 – 6:00 p.m. EDT.

Denali Therapeutics Inc. (NASDAQ: DNLI), a biopharmaceutical company developing a broad portfolio of product candidates engineered to cross the blood-brain barrier (BBB) for neurodegenerative diseases, today announced that Steve Krognes will transition from his role as Chief Financial Officer (CFO) and join the company’s Board of Directors on May 1, 2022.

Delcath Systems, Inc. announced it will host a conference call on March 25, 2022, at 8:30 AM Eastern Time to discuss results for its fourth quarter and full year ended December 31, 2021.

Athersys, Inc. (Nasdaq: ATHX) announced today its financial results for the three months and full year ended December 31, 2021, along with a corporate update.

Dyadic International, Inc. announced that it will report its financial results for 2021 year-end and host a corporate update conference call on Tuesday, March 29, 2022.

POINT Biopharma Global Inc., a company accelerating the discovery, development, and global access to life-changing radiopharmaceuticals, recently announced publication of the dosimetry results from the lead-in cohort of the Phase III mCRPC SPLASH study.